Jessica Best

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Bruce L. Zuraw, William R. Lumry, Douglas Johnston et al. · Journal of Allergy and Clinical Immunology · 2020 · 155 citations · Full text

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

H. James Wedner, Emel Aygören‐Pürsün, Jonathan A. Bernstein et al. · The Journal of Allergy and Clinical Immunology In Practice · 2021 · 59 citations · Full text

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Henriette Farkas, Marcin Stobiecki, Jonny Peter et al. · Clinical and Translational Allergy · 2021 · 50 citations · Full text

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Isao Ohsawa, Daisuke Honda, Yusuke Suzuki et al. · Allergy · 2020 · 45 citations · Full text

Patient perspectives on the treatment burden of injectable medication for hereditary angioedema

Cristine Radojicic, Marc A. Riedl, Timothy Craig et al. · Allergy and Asthma Proceedings · 2021 · 42 citations

Thrombosis, Translational Medicine, Heart Failure +13